OPENING CEREMONY

FACILITATING TRANS-PACIFIC COLLABORATION TO STRENGTHEN ETHICAL BUSINESS PRACTICES
Introductory Remarks
John Andersen, Chair, APEC SME Working Group, Deputy Assistant Secretary of Commerce for the Western Hemisphere, U.S. Department of Commerce
Keynote Remarks
Dr. Patricia García Funegra
Minister of Health, Peru
Announcement of the
2016 APEC Business Ethics Lighthouse Award

Presented by:
Lynn Costa, Project Overseer
Business Ethics for APEC SMEs Initiative
SIGNING CEREMONY
PERU CONSENSUS FRAMEWORK FOR MULTI-STAKEHOLDER ETHICAL COLLABORATION IN THE MEDICAL DEVICE & PHARMACEUTICAL SECTORS

Presented by:
Lynn Costa, Project Overseer
Business Ethics for APEC SMEs Initiative
Rocio Delgado Montero, International Coordinator
DIGEMID, Ministry of Health, Peru
EL MARCO CONSENSUADO PERUANO
PARA LA COLABORACIÓN ÉTICA MULTISECTORIAL
EN LOS SECTORES FARMACÉUTICO Y DE
DISPOSITIVOS MÉDICOS

PERUVIAN CONSENSUS FRAMEWORK
FOR MULTI-STAKEHOLDER ETHICAL
COLLABORATION IN THE PHARMACEUTICAL
AND MEDICAL DEVICE SECTORS

2016
PLENARY PHOTOGRAPH
REGIONAL PROGRESS UPDATE

Presented by:
Andrew Blasi, C&M International
UPDATE FOCUS AREAS

1. Industry Association Code Adoption and Implementation

2. Nanjing Declaration Implementation

3. Other Emerging Considerations
INDUSTRY CODE ADOPTION AND IMPLEMENTATION

BIOPHARMACEUTICAL

MEDICAL DEVICE
KEY TAKEAWAYS ON ASSOCIATION CODE ADOPTION

1. Rapid progress is naturally slowing, as there are much fewer associations without a code of ethics

2. Some associations reluctant or slow to adopt codes

3. At least 3 medical device associations and 15 biopharmaceutical associations in the APEC region that remain without a code or commitment
THE “BIG THREE” IN ASSESSING ASSOCIATION CODE IMPLEMENTATION

1. Governance
2. Alignment
3. Member Implementation
KEY TAKEAWAYS ON ASSOCIATION CODE GOVERNANCE

1. Leadership commitments are firmly in place

2. Code distribution to members and non-industry stakeholders is seeing notable improvement

3. Code resources and local trainings lagging
KEY TAKEAWAYS ON ASSOCIATION CODE ALIGNMENT

1. New and existing codes are intently being aligned with the APEC Principles

2. For the biopharmaceutical sector, code provisions on public sector relationships, clinical trials, and patient organizations are most likely to not be aligned with the APEC Principles
KEY TAKEAWAYS ON ASSOCIATION MEMBER IMPLEMENTATION

1. While both sectors are confident in overall code performance, biopharmaceutical associations report feeling more confident.

2. At least half of the associations in both sectors with codes report a majority of their members have implemented the association’s code.
Nanjing Declaration 2020 Goals

1. Universal industry association codes of ethics
2. Implementation of industry association codes by a majority of their member companies
3. Consensus Frameworks for Multi-Stakeholder Ethical Collaboration in every APEC economy
OTHER EMERGING CONSIDERATIONS

1. Rapid evolution of health care systems and emergence of new stakeholders
2. Industry changes impacting associations
3. Heightened role of health care professionals in serving as active partners with industry to strengthen ethical business practices
NETWORKING COFFEE BREAK

Plenary Dialogue to Recomence at 11:00 AM
PROGRESS DIALOGUE BY APEC ECONOMIES

Session Chair:
Datuk Hafsah Hashim, Chief Executive Officer
Malaysia SME Corporation
NETWORKING LUNCH BREAK

Plenary Dialogue to Recomence at 2:00 PM
DIALOGUE SESSION ONE

Designing and Launching Multi-Stakeholder Ethical Collaborations

Scene-Setting Remarks: Ms. Maria Lourdes C. Santiago, Deputy Director General, Philippines FDA

Session Chair: Mr. Russell Williams, Co-Chair, APEC Biopharmaceutical Working Group on Ethics
SESSION ONE RECOMMENDATIONS

1. Prepare Roadmap by 2017 that outlines steps through 2020;
2. Identification of champions from member economies;
3. Provide continued guidance to economies that conclude multi-stakeholder ethical collaborations;
4. Recruit economies who conclude collaborations to serve as mentors to economies who pursue one; and
5. Collaborations should consider best practices unique to the biopharmaceutical and medical device sectors.
DIALOGUE SESSION TWO
Promoting Strong Ethical Business Practices with Distributors / Third Party Intermediaries

Scene-Setting Remarks: Ms. Bronwen Taylor, Vice President, Compliance and Risk Management, Stryker

Session Chair: Ms. Faye Sumner, Chief Executive Officer, Medical Technology Association of New Zealand
Companies (especially SME’s) engage third parties in overseas markets to:

• Ensure patient and HCP access to innovative, reliable and patient-appropriate medical technology
• Ensure appropriate technology support and service
• Ensure HCP access to education and training in overseas markets

However, these crucial engagements can bring legal and ethical risk...
Third-Party Corruption Liability: Companies Are Accountable for Acts of Agents

- Organizations may be held liable for acts of corruption by their third parties, i.e. their agents, consultants, suppliers, distributors, joint-venture partners, or any individual or entity that has some form of business relationship with the organization.

- Before entering into relationships with third parties, organizations must take active steps to ensure that potential corruption risks stemming from these relationships are responsibly evaluated and managed.

- Conducting risk-based due diligence on third parties has become a legal expectation in many countries that have ratified the OECD Anti-Bribery Convention and/or the United Nations Convention against Corruption.

- Conducting adequate due diligence may help organizations decrease, and even avoid, the risk of criminal culpability for corrupt third-party conduct.
Recent Company Headlines

- 2016: Medical device company must pay $623.2 million to resolve criminal and civil allegations about kickbacks paid to Latin America’s doctors and hospitals, and pay a $22.8 for criminal bribery law violations.

- 2013: Medical device company paid $13.2 million to resolve FCPA violations including bribing doctors and administrators at government controlled hospitals in Argentina, Greece, Mexico, Poland, and Romania.

- 2012: Medical device company paid a criminal fine of $17.3 million in its settlement with the DOJ, and $5.5 million in disgorgement of profits and pre-judgment interest to the SEC. Alleged that company bribed doctors at government hospitals in Argentina, Brazil, and China from 2000 to 2008.

- 2012: Medical device company charged with violating FCPA when a subsidiary paid routine bribes referred to as “chocolates” to Mexican officials in order to obtain lucrative sales contracts with government hospitals. Company to pay $5.2 million to settle the SEC’s charges.

- 2012: PhRMA agreed to pay the U.S. government $29,398,734, in disgorgement of profits, interest and penalties related to bribes paid to government officials to secure business with the government in four countries, including Brazil, in violation of the FCPA. In the case of Brazil, company, through a third-party distributor, paid approximately $70,000 to bribe state government officials so that the state would purchase certain products.
Current KL Principles Text Addresses Third Parties:

“Companies to communicate company policies consistent with the industry code to their third-party intermediaries with the expectation that intermediaries will comply with the industry code.”

But, can we do more?......

Should the APEC business ethics initiative pursue the development of best practice principles on promoting ethical business practices with third party intermediaries to...

• Ensure medical decision making in best interest of patient;
• Mitigate risky legal environments that impede SME access to markets;
• Reinforce self-regulatory approach to manage known legal risk; and
• Maintain industry credibility and public confidence.
Guidance on Compliance Controls

www.advamed.org/Distributor-Relations
Best Practices and Compliance Tools

- Joint Guidance on Managing Third Party SMI Risk
  - Industry’s Top FCPA Risk
  - Industry Wide Tools
    - Compliance Policy
    - Distributor Training Slides
    - Due Diligence Tool

www.advamed.org/Distributor-Relations
Compliance Training Slides (translated)

Training Topics
- Why Compliance with Global Anti-Bribery Laws Matters
- What is Bribery?

Disclaimer and Purpose of Distributor Training Guide
- This training tool is prepared in consultation with, and for the benefit of, the Joint AdvaMed and Eucomed Distributor Working Group.

Distributor Training Tool

This training tool was prepared by Bryan Conway-Matcher and Greg Jancer of Kaye Scholer LLP, in consultation with the Joint AdvaMed and Eucomed Distributor Working Group.
Example Questions for Potential Institution Within an SMI Compliance Questionnaire

Please complete the following questions as completely and thoroughly as possible. All questions must be completed or a written response of "not applicable" must be provided.

SMI Information

1. SMI Name

2. Has your company or any of your company’s principals done business with an SMI in the last 10 years? If so, under what terms?

3. Has your company or any of your company’s principals done business in a similar field in the last 5 years? If so, under what terms?

4. Your Name and Title

5. Full Address

6. Telephone

7. Fax

8. Email

9. Your Company Website

*Note: Unless English is the local language.
Current KL Principles Text Addresses Third Parties:

“Companies to communicate company policies consistent with the industry code to their third-party intermediaries with the expectation that intermediaries will comply with the industry code.”

But, can we do more?......

Should the APEC business ethics initiative pursue the development of best practice principles on promoting ethical business practices with third party intermediaries to...

• Ensure medical decision making in best interest of patient;
• Mitigate risky legal environments that impede SME access to markets;
• Reinforce self-regulatory approach to manage known legal risk; and
• Maintain industry credibility and public confidence.
SESSION TWO RECOMMENDATIONS

1. Expert working group should be convened before the 2017 APEC Business Ethics Forum to prepare draft best practice principles for ethical partnerships with third parties;
2. Organizations have been nominated to coordinate next steps;
3. APEC should ensure inclusive approach that accounts for all third party intermediaries;
4. APEC should drive activities that include (A) alignment of best practices between third parties, manufacturers, and other stakeholders, and (B) capacity-building trainings and resources.
NETWORKING COFFEE BREAK

Plenary Dialogue to Recomence at 4:30 PM
GLOBAL SHOWCASE SESSION

Ensuring an Inclusive and Consultative Approach
Dr. Kenneth Hartigan-Go,
Vice President, Philippine College of Physicians

Harmonizing & Sustaining
One Code of Ethics for Multiple Industry Groups
Dr. Juan Francisco Millán Soberanes,
Director, CETIFARMA (Mexico)

Novel Strategies for Code of Ethics
& Capacity-Building Collaboration between
Industry Associations & Healthcare Professional Bodies
Dr. Andreas Loeﬂer, President, A
Australian Orthopaedic Association

Digital Strategies to Strengthen
Ethical Practices for Third Party Intermediaries
Dr. Sergio Alcântara Madeira, Technical Director,
ABRAIDI (Brazil)

Assuring Ethical Collaborations
between Industry & Patient Organizations
Ms. Leanne Wells, CEO, Consumer Health Forum of Australia
https://www.youtube.com/watch?v=iDTI3M1nTb0
AGREEMENT FOR TRANSPARENCY IN THE RELATIONSHIP BETWEEN PHYSICIANS AND HEALTH CARE INSTITUTIONS WITH THE PHARMACEUTICAL INDUSTRY MEXICO

Mexico, October 2007
Agreement for Transparency
Mexico Consensus

• Signed in 2007 with endorsement of the Government
• Head: General Council of Health (GCH)
• Enforcement mechanism:
  – On 2008 the Health Ministry issued and published an act to enforce the Agreement in all the public sector.
  – 12 public and private signatories are part of the Compliance Committee, which receive complaints.
  – Once the GCH investigates, enforce the comply with the signatories
<table>
<thead>
<tr>
<th>Stakeholders</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public and Social Security Institutions</td>
<td>95% affiliates to the health system</td>
</tr>
<tr>
<td>National Academies and Colleges of physicians</td>
<td>275,517 physicians</td>
</tr>
<tr>
<td>National Association of Private Hospitals</td>
<td>23,269 health units</td>
</tr>
<tr>
<td>Pharma Industry and Medical Devices Sector</td>
<td>204 global and local companies, 95% of market value</td>
</tr>
<tr>
<td>Schools of Medicine</td>
<td>10,000 students</td>
</tr>
</tbody>
</table>

www.cetifarma.org.mx
CLOSING SESSION

Ms. Melissa Stapleton Barnes, Senior Vice President, Enterprise Risk Management and Chief of Ethics and Compliance Officer / Executive Committee, Eli Lilly & Company
Announcement of 2017 APEC Business Ethics for SMEs Forum
Mr. Nguyen Hoa Cuong, Deputy Director-General, 
Agency for Enterprise Development, Ministry of Planning and Investment 
APEC Small and Medium Enterprise Working Group Chair – Designate

Takeaways & Farewell
Ms. Lynn Costa, Project Overseer, 
Business Ethics for APEC SMEs Initiative (The United States)
Economy Groups:

Group A: Peru, Indonesia, Malaysia, Mexico, The United States
Group B: Australia & The Philippines (Limatambo Three)
Group C: China, Canada, & Hong Kong, China (Limatambo Three)
Group D: Viet Nam, Thailand & Japan (Limatambo Three)
Group E: Chile, Brazil, Colombia, New Zealand & Korea (Limatambo Three)

All Other Economies May Select Preferred Group

Emcee

Ms. Kate Hamann
Partner, Pierce Atwood LLP,
Former Intl Policy Counsel,
U.S. Department of Justice